input stringlengths 317 13.1k | output dict |
|---|---|
This expanded access protocol was designed to provide TJ004309 in combination with
atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to
continue with treatment.
;NA;
Inclusion Criteria:
1. Participation in the Tracon sponsored 4309ST101 study and thought to have potential to
... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is
typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can
cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are
available, but MM can come back (relapsed) o... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a prospective, single arm study to investigate the efficacy and safety furmonertinib
80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and
stage IB non-small cell lung cancer. A total of 114 patients would be enrolled. The primary
endpoint is the disease-free survival r... | {
"inclusion_biomarker": [
[
"EGFR mutation"
],
[
"EGFR exon 19 deletion"
],
[
"EGFR L858R"
],
[
"EGFR S768I"
],
[
"EGFR G719X"
],
[
"EGFR L861Q"
],
[
"EGFR T790M"
]
],
"exclusion_biomarker": [
[
"EGFR exon... |
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects
with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk
myelodysplastic syndrome.
;
;
Inclusion Criteria:
1. Men and women ≥ 18 years of age, at the time of signing the ICD (Informed Conse... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a phase 2 study to evaluate the safety and efficacy of the combination of INCMGA00012
and pelareorep and to see how well they work in treating patients with triple negative breast
cancer that has spread to other parts of the body (metastatic).
INCMGA00012 is a monoclonal antibody that works by attaching to t... | {
"inclusion_biomarker": [
[
"ER negative",
"PR negative",
"HER2 negative"
]
],
"exclusion_biomarker": []
} |
In recent years, the goal of stopping drug therapy, also known as treatment-free remission
(TFR), is emerging as one of the management goals of chronic myeloid leukemia (CML) therapy.
Because there is no available data on Asian patients with CML undergoing tyrosine kinase
inhibitor discontinuation (TKI), the investi... | {
"inclusion_biomarker": [
[
"BCR-ABL e13a2"
],
[
"BCR-ABL e14a2"
]
],
"exclusion_biomarker": []
} |
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+
hematologic malignancies.
;
;
Selected Inclusion Criteria:
1. Histologically confirmed relapsed/refractory hematologic malignancies, including
Chronic Lymphocytic Lymphoma (CLL/SLL) and selected Non-Hodgkin's Lymphoma (NHL)
2. ... | {
"inclusion_biomarker": [
[
"CD19 expression"
]
],
"exclusion_biomarker": []
} |
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical
activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in
participants with advanced solid and hematologic cancers.
;NA;
Inclusion Criteria:
- Progressed on standard anticancer therapy or for... | {
"inclusion_biomarker": [
[
"CD20 positive"
]
],
"exclusion_biomarker": []
} |
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal
antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized
anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single
product with the two components of PSB202 enabling a disti... | {
"inclusion_biomarker": [
[
"CD20 expression"
],
[
"CD37 expression"
]
],
"exclusion_biomarker": []
} |
This is a phase 1/2, open label study of D-1553 single agent and combination treatment to
assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and
antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C
mutation.
;NA;
Inclusion criteria
- Subject... | {
"inclusion_biomarker": [
[
"KRas G12C"
]
],
"exclusion_biomarker": []
} |
This is a phase II, prospective, open label, one-center study for evaluation of the addition
of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced
rectal cancer patients. Subjects must have received no prior treatment for rectal cancer
(chemotherapy, radiotherapy or surgery) and no... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus
Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk,
Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled
Study
;
;
Inclusion Criteria:
- Patholog... | {
"inclusion_biomarker": [
[
"CD20 positive"
]
],
"exclusion_biomarker": [
[
"TP53 mutation"
]
]
} |
RAD-18-001 is a First-In-Man, Dose Escalation study conducted at 2 sites. The dose escalation
will be performed based on a 3 + 3 design. Increasing dose levels starting at 1 MBq will be
followed by 2, 4 and 7 MBq. If the highest dose level of 7 MBq is reached without Dose
Limiting Toxicicities (which will stop the d... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
Tumours require a blood supply to provide them with oxygen and nutrients and to enable spread
of cancer through blood vessels to other organs (metastasis). The formation of new blood
vessels is known as angiogenesis, which is controlled by a growth factor (like a hormone)
called Vascular Endothelial Growth Factor (V... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This study will assess the safety, tolerability, and efficacy of multiple dose levels of
PC14586 in participants with advanced solid tumors containing a TP53 Y220C mutation.
;
;
Inclusion Criteria:
- At least 18 years of age or 12 to 17 years of age after adequate adult safety data
become available
- Advanced so... | {
"inclusion_biomarker": [
[
"TP53 Y220C"
]
],
"exclusion_biomarker": []
} |
The purpose of this first in human (FIH) trial is to characterize the safety and tolerability
of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a
recommended dose for future studies in adult patients with advanced solid tumors in selected
indications.
;
;
Inclusion Criter... | {
"inclusion_biomarker": [],
"exclusion_biomarker": [
[
"KRAS activating mutation"
],
[
"NRAS activating mutation"
],
[
"HRAS activating mutation"
],
[
"BRAF activating mutation"
],
[
"PTPN11 activating mutation"
]
]
} |
The incidence of breast reconstruction failure after conventional photon radiotherapy for
breast cancer is about 18.7%. At present, there is limited data on proton radiotherapy for
post operative breast cancer with implantation reconstruction. Proton radiotherapy for breast
cancer can significantly reduce the radiat... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
The purpose of this clinical trial is to evaluate the safety, tolerability and primary
efficacy of JK-1201I in patients with small cell lung cancer (SCLC)
;
;
Inclusion Criteria:
1. Between the age of 18 to 70, male or female;
2. Diagnosed having SCLC via either histology or cytology;
3. Extensive small-cell lun... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The
purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of
DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas
harboring GNAQ/11 mutations.
;
;
In... | {
"inclusion_biomarker": [
[
"GNAQ mutation"
],
[
"GNA11 mutation"
]
],
"exclusion_biomarker": []
} |
An open, multicenter phase II clinical study to evaluate safety and efficacy of HLX208 (BRAF
V600E inhibitor) combined with cetuximab for metastatic colorectal cancer (mCRC) with BRAF
V600E Mutation after first-line treatment
;NA;
Inclusion Criteria:
- Age>=18Y
- Good Organ Function
- Expected survival time ≥ 3 ... | {
"inclusion_biomarker": [
[
"BRAF V600E"
]
],
"exclusion_biomarker": []
} |
For metastatic/advanced NSCLC patients who do not have targetable mutations, either
immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in
combination with platinum doublet chemotherapy is now a standard of care. However, still
about half of the patients do not benefit due to tre... | {
"inclusion_biomarker": [],
"exclusion_biomarker": [
[
"EGFR mutation"
],
[
"BRAF mutation"
],
[
"ALK mutation"
],
[
"ROS1 mutation"
],
[
"NTRAK mutation"
]
]
} |
The purpose of this study is to determine the efficacy of treating patients with intermediate
risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and
lenalidomide (Rd) and patients with high risk SMM with combinational therapy with Rd and
carfilzomib.
;
;
Inclusion Criteria:
Part... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a phase I, first in human, single arm, open label study that will assess safety,
tolerability and clinical activity of FHND6091 when taken orally on a weekly dosing schedule
by patients with relapsed and refractory multiple myeloma (RRMM).The study will consist of
two parts: dose escalation (Part 1) and dose... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
In the current protocol, we propose a study to evaluate a novel, combined esophageal
sponge-methylation biomarker strategy for the early detection of esophageal squamous cell
carcinoma (ESCC) as well as its precursor, esophageal squamous dysplasia (ESD). This strategy
leverages the 'EsophaCap', a swallowable, retrie... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple
myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit
in MM.
;NA;
Inclusion Criteria:
- Adequate bone marrow function
- eGFR ≥ 30 mL/min
- Total bilirubin ≤ 1.5 × upper limit of no... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of
XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
;NA;
Inclusion Criteria:
1. Male or female subjects aged ≥18 years old;
2. Phase I dose escalation period: Histologically or cytologica... | {
"inclusion_biomarker": [
[
"NTRK fusion"
],
[
"ROS1 fusion"
]
],
"exclusion_biomarker": []
} |
Study STML-901-0119 is a dose-escalation study evaluating multiple doses and schedules of
orally administered SL-901 in patients with Advanced Solid Tumors.
;
;
Inclusion Criteria:
1. 18 years old or older.
2. Population by study stage:
1. Part 1a: Patients with advanced, metastatic, and/or progressive solid tum... | {
"inclusion_biomarker": [
[
"PI3K pathway deregulation"
],
[
"DNA-PK pathway deregulation"
]
],
"exclusion_biomarker": []
} |
The Proseven trial is a prospective interventional study that will evaluate the toxicity and
efficacy of MR-guided stereotactic body radiotherapy (SBRT) in the profound hypofractionated
treatment of prostate cancer. Patients will be treated in 5 daily fractions within a short
overall treatment time (OTT) of 7 days. ... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
To evaluate the anti cancer effect of VK 2019 in subjects with EBV related nasopharyngeal
carcinoma (NPC) for whom there is no other standard treatment available
;
;
Inclusion Criteria:
- 1 Informed consent obtained prior to any protocol mandated study specific procedures
in accordance with institutional policies... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a first in human, multicenter, open label, Phase 1a/b dose escalation and dose
expansion study to establish the maximum tolerated dose (MTD), recommended Phase 2 dose
(RP2D), and evaluate the safety and tolerability of QD oral dosing of HC 7366 in a dose
escalating fashion in subjects with advanced solid tum... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
Despite improvements in outcomes for patients with localized Ewing sarcoma, patients with
relapsed metastatic Ewing sarcoma continue to have poor outcomes with current chemotherapy
options. A large body of preclinical data supports a role for IGF-1R inhibition in the
treatment of Ewing sarcoma.
More recently, clini... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
Patients entered into the study will receive ASTX727 orally up to 3 to 8 days prior to
receiving Lutathera treatment to determine whether pre-treatment with ASTX727 results in
re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours.
The study will use [68Ga]-DOTA-TATE PET to image... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
The purpose of this study is to assess the feasibility, safety and efficacy of GD2/CD70
bi-specific CAR-T cell therapy in patients with GD2 and/or CD70 positive tumor. Another goal
of the study is to learn more about the function of the GD2/CD70 bi-specific CAR-T cells and
their persistency in patients.
;
;
Inclu... | {
"inclusion_biomarker": [
[
"GD2 expression"
],
[
"CD70 expression"
]
],
"exclusion_biomarker": []
} |
This phase I/II trial studies the side effects and best dose of avelumab with M6620 in
treating patients with deoxyribonucleic acid (DNA) damage repair (DDR) deficient solid tumors
that have spread to other places in the body (metastatic) or cannot be removed by surgery
(unresectable). DDR deficiency refers to a dec... | {
"inclusion_biomarker": [
[
"ARID1A aberration"
],
[
"ATM aberration"
],
[
"ATR aberration"
],
[
"ATRX aberration"
],
[
"BAP1 aberration"
],
[
"BARD1 aberration"
],
[
"BRCA1 aberration"
],
[
"BRCA2 aberration"... |
HS-10376 is an oral, highly selective, small molecular inhibitor of EGFR/HER2 Exon 20
insertion mutation. This study will evaluate the safety, tolerability, pharmacokinetics and
clinical activity of HS-10376 in Chinese advanced Non-Small Cell Lung Cancer (NSCLC)
patients.
;
;
Inclusion Criteria:
1. Men or women ... | {
"inclusion_biomarker": [
[
"EGFR Exon 20 insertion"
],
[
"HER2 Exon 20 insertion"
]
],
"exclusion_biomarker": []
} |
Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients
(greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma,
advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC)
who have failed all available treatment opti... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant
in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth
factor 2 (HER2)-negative, advanced breast cancer harboring a PIK3CA mutation in Japan, whose
disease has progressed on or after arom... | {
"inclusion_biomarker": [
[
"PIK3CA mutation",
"ER positive",
"HER2 negative"
],
[
"PIK3CA mutation",
"PgR positive",
"HER2 negative"
]
],
"exclusion_biomarker": []
} |
BioEXALK is a prospective study evaluating the biological characteristics of advanced
ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the
national EXPLORE ALK cohort (GFPC 03-2019), a non-interventional, national, multi-center
cohort of ALK-rearranged NSCLC patients.
BioExALK study... | {
"inclusion_biomarker": [
[
"ALK rearrangement"
]
],
"exclusion_biomarker": []
} |
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted
to affect specific genes that are mutated as part of the disease. Mutations in genes can lead
to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of
the following genes; CDKN2C, FGFR3, KR... | {
"inclusion_biomarker": [
[
"CDKN2C mutation"
],
[
"FGFR3 mutation"
],
[
"KRAS mutation"
],
[
"NRAS mutation"
],
[
"BRAF V600E"
],
[
"IDH2 mutation"
],
[
"T(11;14)"
]
],
"exclusion_biomarker": []
} |
This phase II trial studies the effect of larotrectinib in treating patients with NTRK gene
amplification positive solid tumors that have spread to nearby tissues or lymph nodes
(locally advanced) or other places in the body (metastatic). Larotrectinib may stop the
growth of tumor cells by blocking some of the enzym... | {
"inclusion_biomarker": [
[
"NTRK1 amplification"
],
[
"NTRK2 amplification"
],
[
"NTRK3 amplification"
]
],
"exclusion_biomarker": []
} |
In this study, the purpose of this study is to investigate whether prophylactic medical
compression therapy in breast cancer patients receiving docetaxel adjuvant chemotherapy could
reduce the incidence and severity of lymphedema in the upper limbs that received axillary
lymph node resection (sentinel lymph node bio... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a prospective single arm, multi-center, phase II clinical trial to observe the
efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and
Prednisone) in the first-line treatment for patients with marginal zone lymphoma.
;
;
Inclusion Criteria:
1. Age between 18 to 70 years ol... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
The study comprises two phases: Phase 1a and Phase 1b. The purpose of the study is to observe
the safety， tolerability and efficacy of FS-1502.
;
;
Inclusion Criteria:
1. Age ≥18 years at the time of study registration (men and women eligible);
2. Phase Ia dose-escalation study:
Patients with HER2-expressing adv... | {
"inclusion_biomarker": [
[
"HER2 expression"
],
[
"HER2 positive"
]
],
"exclusion_biomarker": []
} |
This is an open-label, multicenter, dose-escalation and parallel-group expansion Phase II
clinical trial to evaluate the efficacy, safety and tolerability of KN026 in combination with
palbociclib and fulvestrant in women or male with HER2-positive metastatic breast cancer .The
subjects will receive 20 mg/kg IV Q2W+ ... | {
"inclusion_biomarker": [
[
"HER2 positive"
]
],
"exclusion_biomarker": []
} |
The purpose of this study is to determine the Predictive value of a SNP signature and liquid
biopsy in patients with natural killer T-cell lymphoma.
;NA;
Inclusion Criteria:
- biopsy proved Natural Killer T-cell Lymphoma
- newly diagnosed patients
Exclusion Criteria:
- patients with biopsy samples unavailable | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or
BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have
activity in patients with homologous recombination defects (HRD).
;
;
Inclusion Criteria:
1. Adults ≥19 years old.
2. Pathologicall... | {
"inclusion_biomarker": [
[
"BRCA1 mutation (germline)"
],
[
"BRCA2 mutation (germline)"
],
[
"BRCA1 mutation (somatic)"
],
[
"BRCA2 mutation (somatic)"
],
[
"ATM mutation"
],
[
"BARD1 mutation"
],
[
"BRIP1 mutation"
],... |
This phase II trial studies how well olaparib works in treating patients with bladder cancer
and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has
spread to other places in the body (advanced or metastatic) and usually cannot be cured or
controlled with treatment. PARPs are proteins... | {
"inclusion_biomarker": [
[
"BRCA1 alteration"
],
[
"BRCA2 alteration"
],
[
"ATM alteration"
],
[
"BAP1 alteration"
],
[
"MSH2 alteration"
],
[
"PALB2 alteration"
],
[
"BRIP1 alteration"
],
[
"ABL1 alteration"... |
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate
the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard
first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers.
Eligible patients include those with unresectable,... | {
"inclusion_biomarker": [
[
"HER2 expression"
],
[
"HER2 expression",
"KRAS wildtype",
"NRAS wildtype",
"BRAF wildtype"
]
],
"exclusion_biomarker": []
} |
The main objective of this trial is to explore the activity of chlorambucil, an alkylating
agent commonly used in chronic lymphocytic leukemia treatment, in metastatic patients, gBRCA,
including VUS, or DDR mutated, previously treated with a platinum-containing chemotherapy.
;
;
Inclusion Criteria:
1. Pathologica... | {
"inclusion_biomarker": [
[
"gBRCA1 deleterious mutation"
],
[
"gBRCA2 deleterious mutation"
],
[
"BRCA1 uncertain significance"
],
[
"BRCA2 uncertain significance"
],
[
"Genetic aberrations associated with HRD"
]
],
"exclusion_biomarker": [
... |
To evaluate the safety and tolerability of sotorasib administered in investigational regimens
in adult participants with KRAS p.G12C mutant advanced solid tumors.
;NA;
Inclusion Criteria:
- Men or women greater than or equal to 18 years old.
- Pathologically documented, locally-advanced or metastatic malignancy wi... | {
"inclusion_biomarker": [
[
"KRAS p.G12C"
]
],
"exclusion_biomarker": []
} |
This is a Phase 1/2, first-in-human, open label, multicenter study to assess safety and
tolerability, antitumor activity, and immunogenic and pharmacodynamic effects of SQZ-eAPC-HPV
as monotherapy and in combination with pembrolizumab in patients with recurrent, locally
advanced, or metastatic HPV16+ solid tumors. T... | {
"inclusion_biomarker": [
[
"HPV16 positive"
]
],
"exclusion_biomarker": []
} |
This phase I trial studies the biological effects of DS-8201a on patients with HER2 positive
cancer that has spread to other places in the body (advanced). DS-8201a works by binding to a
protein called HER2 that is present on the surface of tumor cells. This allows DS-8201a to
kill the tumor cells by damaging their ... | {
"inclusion_biomarker": [
[
"HER2 positive"
],
[
"HER2 expression"
],
[
"HER2 amplification"
],
[
"HER2 mutation"
]
],
"exclusion_biomarker": []
} |
Nivolumab (BMS-936558) is a fully human, IgG4 (kappa) isotype mAb that binds PD-1 on
activated immune cells and disrupts engagement of the receptor with its ligands PD-L1 (B7
H1/CD274) and PD-L2 (B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the
host antitumor response. In early clinical trials,... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
Researchers are looking for a better way to treat people who have advanced non-small cell
lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other
parts of the body.
Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2)
are proteins that help ... | {
"inclusion_biomarker": [
[
"EGFR activating mutation"
],
[
"HER2 activating mutation"
]
],
"exclusion_biomarker": []
} |
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety,
tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of
BLU-222, a selective inhibitor of CDK2.
;
;
Inclusion Criteria:
1. Advanced solid tumors that has progressed beyond standard of care O... | {
"inclusion_biomarker": [
[
"HR positive",
"HER2 positive"
],
[
"CCNE1 amplification"
]
],
"exclusion_biomarker": []
} |
This phase II trial studies how well pembrolizumab works before surgery in treating patients
with mismatch repair deficient solid cancers that have spread to nearby tissue or lymph nodes
(locally advanced). Cancer is caused by changes (mutations) to genes (DNA) that control the
way cells function, and some of these ... | {
"inclusion_biomarker": [
[
"mismatch repair deficient"
],
[
"Microsatellite instability-high"
],
[
"MLH1 loss"
],
[
"PMS2 loss"
],
[
"MSH2 loss"
],
[
"MSH6 loss"
]
],
"exclusion_biomarker": []
} |
To study the radioactive uptake of [68Ga]P137 in the lesion sites of PCa patients and
evaluate the ability of [68Ga]P137 to detect PSMA overexpression in PCa patients (especially
those with recurrent or advanced PCa).
;
;
Inclusion Criteria:
- Men over 18 years of age need to undergo [68Ga]P137 PET/CT examination... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This phase II clinical trial tests a chemotherapy regimen (dose-adjusted etoposide,
prednisone, vincristine, cyclophosphamide and doxorubicin with or without rituximab
[DA-EPOCH+/-R]) with the addition of targeted therapy (tafasitamab) for the treatment of
patients with newly diagnosed Philadelphia chromosome negati... | {
"inclusion_biomarker": [
[
"CD19 positive",
"Philadelphia chromosome negative"
]
],
"exclusion_biomarker": []
} |
This study aims to describe the treatment patterns in clinical practice in adult patients
with mNSCLC with a BRAF V600E mutation. This study will also describe Real-World
Progression-Free Survival (rwPFS) and Overall Survival (OS) for treatments prescribed in
routine practice for mNSCLC with BRAF V600E mutation. Adv... | {
"inclusion_biomarker": [
[
"BRAF V600E"
]
],
"exclusion_biomarker": []
} |
This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and
LY3214996 in the treatment of KRAS mutant cancers will be studied.
;
;
Inclusion Criteria:
1. Part A: Histological or cytological proof of advanced KRASm NSCLC, CRC or PDAC; PART
B: Histological or cytological proof of advan... | {
"inclusion_biomarker": [
[
"KRAS mutation"
]
],
"exclusion_biomarker": [
[
"NRAS mutation"
],
[
"RAS Q61"
],
[
"KRAS G13"
],
[
"BRAF class 1 mutation"
],
[
"BRAF class 2 mutation"
],
[
"BRAF unclassified mutation"
... |
This is a surgical biospecimen collection study. The purpose of this study is to understand
how much of two drugs (dabrafenib and trametinib) are able to penetrate brain tumors and turn
off the RAF signaling pathway. This is important because these drugs are currently FDA
approved for other tumors and may have effic... | {
"inclusion_biomarker": [
[
"BRAF V600E"
],
[
"BRAF V600K"
],
[
"BRAF V600R"
],
[
"BRAF V600D"
]
],
"exclusion_biomarker": []
} |
transoral Robotic surgery for rECurrent tumours of the Upper aerodigestive Tract
;
;
Inclusion Criteria:
- Aged over 18
- Previous HNC treated with radiotherapy
- Undergoing TORS as part of their management for recurrent disease
- Surgery performed on or before July 31st 2018.
Exclusion Criteria:
- TORS used i... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a single-arm, multicenter, exploratory clinical study to evaluate the safety and
efficacy of the combination of etoposide, cytarabine and PEG-rhG-CSF (EAP regimen) on
hematopoietic stem cell mobilization in poor mobilization patients with hematological
malignancies. All eligible patients will receive EAP reg... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to
evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I
neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).
;NA;
Inclusion Criteria:
- Patients who voluntarily ... | {
"inclusion_biomarker": [
[
"NF1 mutation (germline)"
]
],
"exclusion_biomarker": []
} |
This is a first-in-human, Phase I, open-label, dose-escalation and expansion study designed
to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary
efficacy of PT199 (an Anti-CD73 mAb) alone and in combination with a PD-1 inhibitor, in
patients with locally advanced or metastatic so... | {
"inclusion_biomarker": [
[
"CD73 expression"
],
[
"PD-L1 expression"
]
],
"exclusion_biomarker": []
} |
The purpose of this study is to assess the safety and tolerability and determine the
recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with
relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer.
;
;
Inclusion Criteria:
1. Willing and able to pa... | {
"inclusion_biomarker": [
[
"ICAM-1 expression",
"BRAF wild-type"
],
[
"ICAM-1 expression",
"BRAF mutation"
]
],
"exclusion_biomarker": []
} |
This open-label phase II trial studies how well niraparib works in treating patients with
advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation /
alteration. Niraparib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. The trial is designed... | {
"inclusion_biomarker": [
[
"ARID1A mutation"
],
[
"ARID1B mutation"
],
[
"ARID2 mutation"
],
[
"ATM mutation"
],
[
"ATR mutation"
],
[
"ATRX mutation"
],
[
"BARD1 mutation"
],
[
"BRCA1 mutation"
],
[
... |
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used
in medical research.
Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to
join this study if it has come back after remission or is not responding to treatment.
;
;
Inclusion Criter... | {
"inclusion_biomarker": [
[
"FLT3 ITD"
]
],
"exclusion_biomarker": []
} |
Multicenter, retrospective and prospective, cohort, observational study evaluating the
clinical efficacy and tolerability of Eribulin as second-line treatment in accordance with
the indications authorized by AIFA in patients with triple negative advanced breast cancer in
a real world setting.
;
;
Inclusion Criter... | {
"inclusion_biomarker": [
[
"HR negative",
"HER2 negative"
]
],
"exclusion_biomarker": [
[
"HER2 positive"
],
[
"HR positive"
]
]
} |
Diffuse intrinsic pontine gliomas (DIPGs), which diffusely occupy the pons of brainstem, are
the deadliest primary brain cancer in children. Biopsy for pathology plus radiotherapy
remains the current standard-of-care treatment that is minimal effective. Thus, the median
overall survival after diagnosis is just 10 mo... | {
"inclusion_biomarker": [
[
"HLA-A2 subtype"
],
[
"H3.3 K27M"
]
],
"exclusion_biomarker": []
} |
The ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed
for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the
proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the
maximum tolerated dose of BAY1895344 that ... | {
"inclusion_biomarker": [
[
"ATM deleterious mutation"
],
[
"ATM low expression"
],
[
"ATM loss"
],
[
"DDR deficiency",
"estrogen-receptor positive"
],
[
"DDR deficiency",
"progesterone-receptor positive"
],
[
"DDR deficiency... |
The purpose of this single arm,phase Ⅱ clinical trail is to determine the safety and efficacy
of docetaxel and cisplatin combined with Nimotuzumab in the treatment of recurrent and
metastatic nasopharyngeal carcinoma
;NA;
Inclusion Criteria:
- biopsy proved nasopharyngeal carcinoma;
- stage IVc according to Union... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an
Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1
;
;
Inclusion Criteria:
Part A
1. Subject must be at least 18 years old and must have histologically confirmed,
unresectable, locally adva... | {
"inclusion_biomarker": [
[
"PD-L1 expression"
]
],
"exclusion_biomarker": []
} |
BRAF mutation exists in about 10-12% of colorectal cancer, among which BRAF V600E mutation is
the most common type, which is an important biomarker for predicting the prognosis and
precise treatment efficacy of metastatic colorectal cancer (mCRC). The prognosis of
metastatic colorectal cancer with BRAF V600E mutatio... | {
"inclusion_biomarker": [
[
"BRAF V600E",
"MSS"
],
[
"BRAF V600E",
"pMMR"
]
],
"exclusion_biomarker": []
} |
The purpose of this study is to evaluate the efficacy and safety of selinexor as a
maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a
partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid
Tumors version 1.1 [RECIST v 1.1]) after completi... | {
"inclusion_biomarker": [
[
"TP53 wt"
]
],
"exclusion_biomarker": []
} |
This study will be a single arm multicenter Phase II open-label, dose escalation study of
asciminib in patients with CML-CP without T315I mutation who have had 1 prior TKIs for which
they did not respond to treatment or were intolerant to treatment.
;
;
Inclusion Criteria:
Signed informed consent must be obtained... | {
"inclusion_biomarker": [
[
"BCR-ABL1 mutation"
],
[
"CCA/Ph positive"
]
],
"exclusion_biomarker": []
} |
This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T
cells when given together with chemotherapy and NKTR-255, and to see how well they work in
treating patients with CD19 positive B acute lymphoblastic leukemia that has come back or
does not respond to treatment. A CAR is a gen... | {
"inclusion_biomarker": [
[
"Philadelphia Chromosome positive"
],
[
"CD19 expression"
]
],
"exclusion_biomarker": []
} |
Selitrectinib expanded access is for minor and adult patients with cancer having a change in
a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an
ongoing selitrectinib clinical trial or have other considerations that prevent access to
selitrectinib through an existing clinical t... | {
"inclusion_biomarker": [
[
"NTRK1 fusion"
],
[
"NTRK2 fusion"
],
[
"NTRK3 fusion"
]
],
"exclusion_biomarker": []
} |
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to
evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-21668 in
solid tumor patients. In dose escalation phase, biomarker status is not required, but in dose
expansion phase patients are required... | {
"inclusion_biomarker": [
[
"PIK3CA mutation"
]
],
"exclusion_biomarker": []
} |
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of
talazoparib when given in combination with palbociclib, axitinib, or crizotinib in treating
patients with solid tumors that has spread to nearby tissue or lymph nodes (locally advanced)
or other places in the body (metastatic)... | {
"inclusion_biomarker": [
[
"BRCA1 defect"
],
[
"BRCA2 defect"
],
[
"PALB2 defect"
],
[
"RAD51C defect"
],
[
"RAD51D defect"
],
[
"MET mutation"
],
[
"MET amplification"
],
[
"MET overexpression"
],
[
... |
This ComboMATCH phase II trial compares the usual treatment alone (fulvestrant) to using
binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer
that has spread to other places in the body (metastatic) and has an NF1 genetic change.
Fulvestrant is a hormonal therapy that binds t... | {
"inclusion_biomarker": [
[
"NF1 nonsense mutation",
"ER positive",
"HER2 negative"
],
[
"NF1 frameshift mutation",
"ER positive",
"HER2 negative"
],
[
"NF1 deletion",
"ER positive",
"HER2 negative"
],
[
"NF1 nonsense mutation",
... |
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, dose-escalation, and
dose-optimization study to evaluate the safety and clinical activity of PBCAR0191 in adults
with r/r B ALL (Cohort A) and in adults with r/r B-cell NHL (Cohort N) and identify a
treatment regimen most likely to result in clini... | {
"inclusion_biomarker": [
[
"CD19 positive"
]
],
"exclusion_biomarker": []
} |
TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat
participants who have relapsed or refractory multiple myeloma (RRMM).
The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination
with anti-CD38 (mAbs) and to determine the recommended Phase 2... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of
HLX208 for advanced melanoma with BRAF V600 mutation
;NA;
Inclusion Criteria:
- Age>=18Y
- Good Organ Function
- Expected survival time ≥ 3 months
- advanced melanoma with BRAF V600 mutation that have been diagnosed
- ECOG... | {
"inclusion_biomarker": [
[
"BRAF V600"
]
],
"exclusion_biomarker": []
} |
This is a Phase II study for patients with MIBG avid tumors. The study is to determine the
response rate to <131>I-MIBG in patients with de novo, relapsed or refractory neuroblastoma
or other MIBG avid malignant tumors 42 days post MIBG therapy. It will also be evaluating the
tolerability and safety of the study age... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE
combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment
will continue until disease progression or intolerable toxicity or patients withdrawal of
consent,and the target sample size is 60 indivi... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
Numerous evidences verified that erlotinib could dramatically improve the PFS and OS of
non-small cell lung cancers who harbor EGFR sensitive mutations, however, primary or
secondary resistance will be developed after TKI treatment, doctors do plenty of researches
to overcome TKI resistance. FAST ACT-2 study present... | {
"inclusion_biomarker": [
[
"EGFR exon 19 del"
],
[
"EGFR exon 21 L858R"
]
],
"exclusion_biomarker": []
} |
This phase II trial studies the side effects and how well azacitidine and enasidenib work in
treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
;
;
Inclusion Criteria:
- Signed, informe... | {
"inclusion_biomarker": [
[
"IDH2 R140"
],
[
"IDH2 R172"
],
[
"IDH2 R140",
"TP53 mutation"
],
[
"IDH2 R172",
"TP53 mutation"
],
[
"IDH2 R140",
"ASXL1 mutation"
],
[
"IDH2 R172",
"ASXL1 mutation"
],
[
... |
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This Phase I study
will be conducted in HSV-seropositive subjects with advanced malignant solid tumors that are
refractory to conventional therapies. This is an open label study to determine the safety and
tolerability of VG161, and recommended d... | {
"inclusion_biomarker": [],
"exclusion_biomarker": []
} |
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination
with nivolumab in patients with metastatic or advanced epithelial tumours.
To characterize the safety and tolerability of NG-641 in combination with nivolumab in
patients with metastatic or advanced epithelial tumours and t... | {
"inclusion_biomarker": [
[
"MSI-high"
],
[
"dMMR"
]
],
"exclusion_biomarker": []
} |
This is a global, multicenter, open-label pre-approval access program to provide access to
pralsetinib (BLU-667) until such time that pralsetinib becomes available through other
mechanisms or the Sponsor chooses to discontinue the program.
;NA;
Inclusion Criteria:
1a. Pathologically documented and definitively dia... | {
"inclusion_biomarker": [
[
"RET fusion"
],
[
"RET fusion",
"EGFR mutation"
],
[
"RET fusion",
"ALK mutation"
],
[
"RET fusion",
"ROS1 mutation"
],
[
"RET fusion",
"NTRK mutation"
],
[
"RET fusion",
"BRAF mu... |
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and
cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and
antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor
malignancies.
;
;
Key Criteria:
Parts 1a and 1b ... | {
"inclusion_biomarker": [
[
"ER positive"
],
[
"KRAS activating mutation"
],
[
"ER positive",
"FGFR amplification"
],
[
"ER positive",
"HER2 positive"
],
[
"KRAS G12C"
],
[
"ER positive",
"HER2 negative"
],
[
... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.